Drug Profile

Research programme: T cell therapeutics - Bristol Myers Squibb/Immatics N.V.

Alternative Names: TCRT therapy-Immatics Biotechnologies/Celgene Corporation

Latest Information Update: 08 May 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator immatics biotechnologies GmbH
Developer Immatics N.V.
Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

01 May 2023 Bristol Myers Squibb has exercised its option and entered into licensing agreement with Immatics for the development of T cell therapeutics for Cancer worldwide
25 May 2021 Preclinical trials in Cancer in USA, Germany (Parenteral) (Immatics pipeline, May 2021)
01 Jul 2020 Immatics N.V and Immatics Biotechnologies GmbH combined to form Immatics N.V.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com